HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

PET Imagining in Cardiac Amyloidosis

NYU Langone

S. Dorbala

How to Make the Diagnosis of ATTR Amyloidosis

Scripps Health

B. Sperry

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Transplant in Amyloidosis

Scripps Health

M. Urey

Using Cardiac MRI to Assess Progression and Treatment Response

The France Foundation

D. Kwon

Cardiomyopathies: 2024 Wrap Up

Cardiology 2024 Year in Review

A. Masri

Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

Cardiac Amyloidosis: An Overlooked but Treatable Cause of HFpEF

Inova Heart and Vascular Institute - Advanced Heart Failure Symposium

Emerging Therapies in Cardiac Amyloidosis

NYU Langone

M. Hanna

When to Suspect Amyloidosis

Scripps Health

S. Cuddy

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

Cardiac Amyloidosis: Evaluation and New Therapies

Cleveland Clinic Heart, Vascular and Thoracic Institute

M. Hanna

Therapies for Pulmonary Venous Hypertension: Updates on the Treatmen…

Scripps Health

R. Mohan

Lessons from the 2023 ACC Expert Consensus Decision Pathway on Compr…

Michelle Kittleson

Clinical Presentation of Amyloidosis: Who to Suspect? - a 2022 Update

Scripps Health

R. Mohan

Glucagon Like Peptide 1 Receptor Agonists Use and Outcomes in Cardia…

Vikash Jaiwal

Cardiac Amyloidosis: Transition from a Rare, Underdiagnosed and Untr…

The Texas Heart Institute

M. Maurer

AHA 2022: Genomic Therapies for Hereditary Transthyretin (TTR) Amylo…

AHA 2022 Conference Coverage

M. Fontana